{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:29:02Z","timestamp":1792250942171,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While testosterone replacement therapy (TRT) is generally effective in restoring testosterone levels and improving quality of life, its dermatological adverse effects are underreported compared to cardiovascular and oncologic risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review aims to synthesize existing evidence on cutaneous complications associated with TRT to better inform clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted using PubMed, Scopus, and Cochrane databases to identify studies reporting dermatologic adverse events related to TRT in adult men. Inclusion criteria focused on original studies documenting skin-related side effects in TRT recipients. Ten studies met eligibility: eight prospective clinical trials and two retrospective chart reviews published between 2006 and 2025. Data were extracted and summarized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across all included studies, dermatologic adverse events were consistently reported. Acne was the most frequent, affecting 0.6%-9.1% of participants, with the lowest incidence in oral formulations. Pruritus occurred in up to 10.0%, rashes in up to 5.3%, and abnormal hair growth in up to 5.3%. Injectable formulations were generally associated with higher rates of acne and systemic reactions than topical or oral preparations. Despite the prevalence of these effects, most studies lacked standardized reporting or detailed management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dermatologic side effects of TRT, though often considered non-severe, can significantly impact patient satisfaction, adherence, and quality of life. Acne and other cutaneous reactions vary by delivery method and patient susceptibility, emphasizing the need for clinician awareness, patient counseling, and better adverse event reporting. Future research should standardize dermatologic outcome measures and explore effective prevention and management strategies to improve the safety and tolerability of TRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sxmrev\/qeaf061","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:16:37Z","timestamp":1759925797000},"source":"Crossref","is-referenced-by-count":3,"title":["Dermatological adverse effects of testosterone replacement therapy: a scoping review of the literature"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-896X","authenticated-orcid":false,"given":"Elia","family":"Abou Chawareb","sequence":"first","affiliation":[{"name":"Department of Urology, University of California , Irvine, Irvine, CA 92697 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Campos","sequence":"additional","affiliation":[{"name":"Department of Urology, Universidade Federal de Minas Gerais , Belo Horizonte, Minas Gerais 30130-100 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Savio","sequence":"additional","affiliation":[{"name":"Department of Urology, Benefic\u00eancia Portuguesa de S\u00e3o Paulo , Bela Vista, S\u00e3o Paulo 01323-001 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hartman-Kenzler","sequence":"additional","affiliation":[{"name":"Department of Urology, Stony Brook Medicine , Stony Brook, NY 11794 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, Irvine, CA 92697 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-1364","authenticated-orcid":false,"given":"Muhammed A M","family":"Hammad","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, Irvine, CA 92697 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A","family":"Yafi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, Irvine, CA 92697 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"12","key":"2026010505512726800_ref1","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1111\/j.1743-6109.2008.00988.x","article-title":"Erectile dysfunction and comorbidities in aging men: an urban cross-sectional study in Malaysia","volume":"5","author":"Khoo","year":"2008","journal-title":"J Sex Med"},{"issue":"2","key":"2026010505512726800_ref2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00345-009-0440-y","article-title":"Vascular risk factors and their association to serum androgen levels in a population-based cohort of 75-year-old men over 5 years: results of the VITA study","volume":"28","author":"Ponholzer","year":"2010","journal-title":"World J Urol"},{"issue":"11","key":"2026010505512726800_ref3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.metabol.2006.06.019","article-title":"Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong","volume":"55","author":"Wong","year":"2006","journal-title":"Metabolism"},{"issue":"7","key":"2026010505512726800_ref4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"key":"2026010505512726800_ref5","article-title":"Testosterone replacement therapy market forecast report 2025-2033, with key player profiles for AbbVie, Clarus therapeutics, Ferring Pharmaceuticals, lupin, Pfizer, Teva Pharmaceuticals and more","author":"Markets","year":"2025"},{"issue":"2","key":"2026010505512726800_ref6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"2026010505512726800_ref7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.eururo.2025.04.010","article-title":"European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease","volume":"88","author":"Salonia","year":"2025","journal-title":"Eur Urol"},{"issue":"5","key":"2026010505512726800_ref8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society* clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"2026010505512726800_ref9","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2025.9904","article-title":"Management of Adverse Effects in testosterone replacement therapy","volume":"51","author":"Basheer","year":"2025","journal-title":"Int Braz J Urol"},{"issue":"8","key":"2026010505512726800_ref10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant","year":"2020","journal-title":"Urol Oncol"},{"issue":"6 Pt 1","key":"2026010505512726800_ref11","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1097\/01.ju.0000091104.71869.8e","article-title":"Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia","volume":"170","author":"Rhoden","year":"2003","journal-title":"J Urol"},{"issue":"10","key":"2026010505512726800_ref12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.urolonc.2019.06.007","article-title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis","volume":"37","author":"Kardoust Parizi","year":"2019","journal-title":"Urol Oncol"},{"issue":"7","key":"2026010505512726800_ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073535","article-title":"The role of testosterone in the elderly: what do we know?","volume":"23","author":"Barone","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026010505512726800_ref14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ucl.2016.01.006","article-title":"Testosterone and male infertility","volume":"43","author":"Ohlander","year":"2016","journal-title":"Urol Clin North Am"},{"issue":"4","key":"2026010505512726800_ref15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ucl.2022.07.003","article-title":"Current management and controversies surrounding andropause","volume":"49","author":"Mian","year":"2022","journal-title":"Urol Clin North Am"},{"issue":"2","key":"2026010505512726800_ref16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clindermatol.2016.10.004","article-title":"Sex hormones and acne","volume":"35","author":"Ju","year":"2017","journal-title":"Clin Dermatol"},{"issue":"Suppl 4","key":"2026010505512726800_ref17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0625.2004.00255.x","article-title":"Androgen action on human skin -- from basic research to clinical significance","volume":"13","author":"Zouboulis","year":"2004","journal-title":"Exp Dermatol"},{"issue":"5","key":"2026010505512726800_ref18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1056\/NEJMra022251","article-title":"Risks of testosterone-replacement therapy and recommendations for monitoring","volume":"350","author":"Rhoden","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"2026010505512726800_ref19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/bju.12037","article-title":"Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study","volume":"111","author":"Tan","year":"2013","journal-title":"BJU Int"},{"issue":"8","key":"2026010505512726800_ref20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/BF03346421","article-title":"Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism","volume":"31","author":"Minnemann","year":"2008","journal-title":"J Endocrinol Investig"},{"key":"2026010505512726800_ref21","doi-asserted-by":"publisher","first-page":"1756287220937232","DOI":"10.1177\/1756287220937232","article-title":"A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men","volume":"12","author":"Swerdloff","year":"2020","journal-title":"Ther Adv Urol"},{"issue":"11","key":"2026010505512726800_ref22","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1111\/j.1743-6109.2010.01994.x","article-title":"Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints","volume":"7","author":"Permpongkosol","year":"2010","journal-title":"J Sex Med"},{"issue":"4","key":"2026010505512726800_ref23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/sm2.80","article-title":"Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study","volume":"3","author":"Kaminetsky","year":"2015","journal-title":"Sex Med"},{"issue":"5","key":"2026010505512726800_ref24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2164\/jandrol.109.009597","article-title":"Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial","volume":"31","author":"Wang","year":"2010","journal-title":"J Androl"},{"issue":"2","key":"2026010505512726800_ref25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2005.10.022","article-title":"Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease","volume":"47","author":"Brockenbrough","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2026010505512726800_ref26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/andr.13747","article-title":"Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism","volume":"13","author":"Miner","year":"2025","journal-title":"Andrology"},{"issue":"2","key":"2026010505512726800_ref27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026010505512726800_ref28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jsxm.2016.06.003","article-title":"Effects of 8-year treatment of long-acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism","volume":"13","author":"Permpongkosol","year":"2016","journal-title":"J Sex Med"},{"key":"2026010505512726800_ref29","doi-asserted-by":"publisher","first-page":"20503121211051546","DOI":"10.1177\/20503121211051546","article-title":"Effects of testosterone treatment on transgender males: a single-institution study","volume":"9","author":"Korpaisarn","year":"2021","journal-title":"SAGE Open Med"},{"issue":"9","key":"2026010505512726800_ref30","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1111\/1346-8138.16066","article-title":"2020 guidelines for the diagnosis and treatment of cutaneous pruritus","volume":"48","author":"Satoh","year":"2021","journal-title":"J Dermatol"},{"issue":"2","key":"2026010505512726800_ref31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/andr.13108","article-title":"Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age","volume":"10","author":"Pastuszak","year":"2022","journal-title":"Andrology"},{"issue":"1","key":"2026010505512726800_ref32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.xfnr.2020.11.001","article-title":"Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects","volume":"2","author":"Khodamoradi","year":"2021","journal-title":"F S Rev"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smr\/advance-article-pdf\/doi\/10.1093\/sxmrev\/qeaf061\/65131094\/qeaf061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smr\/advance-article-pdf\/doi\/10.1093\/sxmrev\/qeaf061\/65131094\/qeaf061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:51:46Z","timestamp":1767610306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smr\/article\/doi\/10.1093\/sxmrev\/qeaf061\/8313420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/sxmrev\/qeaf061","relation":{},"ISSN":["2050-0513","2050-0521"],"issn-type":[{"value":"2050-0513","type":"print"},{"value":"2050-0521","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,3]]},"article-number":"qeaf061"}}